Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.

Not Applicable

Terminated

• Conditions: Liver Cancer, Adult
• Interventions: Drug: RopivacaIne chlorhydrate; Drug: Placebo

• Registration Number: NCT02527577
• Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Brief Summary

The indications liver cancer surgery currently booming due to the increase in surgical techniques and instruments for a more secure resection of liver tissue with a significant reduction in bleeding or surgical complications. This allowed to expand surgical indications in the most fragile patients so assuming optimized anesthetic care.

So far, the technique of analgesia reference to this surgery remains administration of morphine analgesia via a device controlled by the patient (PCA) for epidural analgesia is against-indicated because of induced bleeding disorders by surgery.

Rafi then McDonnell in 2007 have described a new technique of loco regional anesthesia, the abdomen of the Transversus Abdominis Plane (TAP) nerve block(TAP), which allows selective anesthesia of the abdominal wall. But parietal pain related muscular and nervous sagging surgical approach represent a significant share of post operative pain.

This study proposes an evaluation of the abdomen transverse blocks in hepatectomy.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04
• Primary Completion: 2014-09
• Study Completion: 2015-02
• Status Verified: 2015-07
• Study First Submitted: 2015-08-14
• Study First Submitted QC: 2015-08-17
• Last Update Submitted: 2015-08-17
• Study First Posted: 2015-08-19
• Last Update Posted: 2015-08-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

• hepatectomy or segmentectomy

Exclusion Criteria

• Sepsis uncontrolled current
• Overdose in anticoagulant during general anesthesia
• Thrombocytopenia <50 g / dl
• Severe renal impairment: Cockcroft <30 ml / min
• history of ventricular arrhythmia serious unexplained .*
• Allergy to local anesthetics of the amide
• Contraindication to remifentanil and morphine
• Hypovolemia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ropivacaïne chlorhydrate monohydrate	RopivacaIne chlorhydrate	-
placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
consumption of morphine over the first 48 hours postoperative.	at 48 hours postoperative

Secondary Outcome Measures

Name	Time	Method
pharmacokinetic of ropivacaine (plasma concentrations)	1, 2, 3, 6, 10, 24, 36, 48 hours post-dose

Trial Locations

Locations (1)

CHU de SAINT-ETIENNE; 🇫🇷 Saint-etienne, France